

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Sofosbuvir for treating chronic hepatitis C**

**Batch 28**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was raised during consultation that hepatitis C adversely affects certain populations, who could be considered at risk of being disadvantaged in terms of accessing the healthcare system and therefore at risk of inequity of access to innovative new treatments (such as certain immigrant populations, prison populations and people who inject drugs).

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Attendees at the scoping workshop agreed that this issue related to implementation and could not be addressed through technology appraisal recommendations.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?
---

No
----

**Approved by Associate Director (name):** Helen Knight

**Date:** 25/11/2013